Cutaneous malignant melanoma metastatic to the eye is rare but has been documented. The usual presentation is after the diagnosis of 
Metastatic melanoma to the eye is considered to be rare. The distiction between metastatic and primary melanoma is important because the prognosis and methods of treatment differ. Metastatic cutaneous melanoma generally indicates a grave outcome. 1 We report a patient with a history of cutaneous melanoma presenting with anterior segment metastasis who subsequently developed rubeotic glaucoma.
Case report
A 40-year-old Caucasian farmer presented with floaters and hazy vision of a few weeks' duration. Visual acuity at presentation was 6/12 right and 6/6 left. Marked anterior chamber cells and flare, a few mutton fat keratic precipitates and rubeosis iridis were noted. The intraocular pressure was normal at presentation. The right iris appeared pushed forward at the 9 o'clock position and gonioscopy after dilation revealed a grey mass at the ciliary body (Fig. 1) . Fundal examination was unremarkable. A malignant melanoma had been removed from his back 2 years prior to ophthalmic presentation and axillary secondaries removed a year later. Systemic investigation revealed no further evidence of metastasis. A presumptive diagnosis of K. RAMAESH, J.W.V. MARSHALL, S.B. WHARTON, B. DHILLON metastatic melanoma to the ciliary body was made. A month after ophthalmic presentation the intraocular pressure rose to 40 mmHg with evidence of rubeosis. Tumour regression did not occur with external beam radiation (total radiation 1000 Gy over three fractions). In view of the intractable pain and poor vision the right eye was enucleated. Four months after enucleation the patient died of cerebral metastases.
Gross pathological examination of the globe (24 X 25 X 23 mm) showed a white dumb-bell shaped tumour in the posterior chamber measuring 5 mm in diameter attached to the iris and adherent to the lens (Fig. 2) .
Microscopy confirmed tumour attached to the iris extending in an irregular sheet across the ciliary body ( Fig. 3) but sparing the retina. Tumour cells were also seen in the anterior chamber drainage angle. The tumour deposits were composed of polygonal cells with ovoid nuclei and prominent nucleoli. There were widespread mitotic figures and multifocal necrosis. Melanin pigmentation was scanty. No associated naevoid component was identified. Melanin stains were focally positive and immunocytochemistry demonstrated a positive staining reaction with antibodies to S100 and neuron-specific enolase, with patchy weak reaction to HMB-45. A histological diagnosis of intraocular metastatic melanoma from a cutaneous primary was made.
Comment
Differentiation between metastatic melanoma and primary melanoma of the eye has significant clinical consequences. A high index of suspicion is essential when approaching such cases as the patient may not volunteer information relating to the previous excision of pigmented cutaneous lesions. Cutaneous melanoma presenting for the first time with intraocular metastases is rare. However Font et al? reported two cases in which pres�nting features were hyphaema, therapy-resistant iritis, pain and proptosis. Nevertheless metastatic cutaneous melanoma to the eye may remain asymptomatic ?
Visual loss and blurring may be attributed to media opacity. 4 , 5 Pigment dispersion in the aqueous, anterior vitreous and deposition over the lens surface contribute to media opacity. 4 , 6 In addition iris nodules, prominent sentinel vessels, heterochromia iridis, hyphaema, iritis and secondary glaucoma have been described. 5 ,7-9 The incidence of ocular metastasis of cutaneous melanoma is rare and has not been determined accurately. Shields et aI. 1 8 reported 40 cases of metastatic tumour to the iris, 3 (8%) of which were from cutaneous melanoma. However, in combined data from three series only 1% of ocular metastases were from cutaneous melanoma. 19 Gupta and Brasfield2 0 reported the incidence to be only 0.46%, but of 15 consecutive patients who died of metastatic cutaneous malignant melanoma, 33% were found to have intraocular metastases at autopsy. 17 Primary choroidal melanoma metastasising to cutaneous tissue is not infrequent and CharI reported an incidence of 36% after a median follow-up of 4 years.
From the literature we identified 79 locations in 68 eyes. Fifty (75%) uveal, 39 (49%) vitreo-retinal and 11 (13%) anterior chamber locations were identified. These figures show that uveal metastasis is commoner than metastasis to retino-vitreal locations (Table 1) .
Differentiating features of primary uveal melanomas and metastatic cutaneous melanoma have been described. A past history of cutaneous malignancy and aggressive growth favour the diagnosis of metastasis. Primary iris melanomas tend to be of low-grade spindle cell type and may extend circumferentially. The tumour we report was of high grade, attached to, but not within the iris and spread as a sheet over the ciliary body, raising questions as to the site of entry into the eye. Primary choroidal melanomas are bulky, solitary, and consist of mixed spindle and epithelioid cells following Callender's classification? Secondary melanomatous deposits in the choroid tend to be flat and multifocal, are epitheloid and evolve from tumour emboli. 2, 15 Bilateral primary malignant melanoma is virtually an unknown entity?2 Special characteristics of vitreo-retinal metastases from skin melanoma are golden-brown cells in the vitreous, vitreous plaques and clusters of vitreous cells on the retinal surface without discrete tumour mass ? Anterior segment features suggestive of metastasis are pigment dispersion in the aqueous, black hypopyon and deposition over the lens.
Treatment of metastatic cutaneous melanoma to the eye has not been well defined. Therapeutic regimens to date have had varied success in inducing ocular tumour regression, although some treatment modalities have been unsuccessful. Therapeutic measures that have been advocated are enucleation,4,8,23 external beam radiation, 1 4 chemotherapy,7, 15 transfer factor, interferon and BCG vaccine. 9 Intractable pain due to rubeotic glaucoma in a blind eye is considered to be an indication for enucleation. 4, 8, 23 In the case we report tumour regression failed to occur with external beam radiation; similarly others found combined external beam radiation and intravenous vindesine failed to induce tumour regression. 8 Various chemotherapeutic agents have been used. Intravenous dicarbamazine, hydroxyurea and BCG vaccination resulted in intraocular tumour regression but failed to induce systemic regression.9 A bilateral metastatic uveal tumour from cutaneous melanoma was successfully managed with systemic BCNU (1,3-bis(2-chloroethyl)-I-nitrosuria) in one case.24 However, combined administration of repeated systemic and subconjunctival DTIC (5-(3,3-dimethyl-l triazene)imidazol-4-carboxamide) and BCNU were unsuccessful in promoting tumour regression. 13 It is interesting to note spontaneous regression has been reported in an eye with the development of black hypopyon.I O The majority of the patients at the time of ocular presentation had secondary deposits to regional lymph nodes, the central nervous system and viscera including lung, liver, gastrointestinal tract, pancreas, adrenal, heart, kidney, thyrOid and spleen? O The primary tumour metastasising to the eye.is predominantly of the superficial spreading varietyP however, the nodular variety, which has the worst systemic prognosis, has also been reported.8
The time interval between diagnosis of skin primary and ocular manifestation varied from 18 to 56 months ? Prognosis for survival varied similarly between 1 and 15 months.
In summary, this is a case of symptomatic metastatic melanoma to the posterior chamber attached to the anterior uveal tract and lens from a cutaneous primary, presenting with features of blurred vision, rubeosis iridis and later developing rubeotic glaucoma. Metastatic cutaneous malignant melanoma to the uveal tract is uncommon and involvement of the iris is rarer still. As the therapeutic measures for cutaneous melanoma improve, ocular metastasis may become a more common clinical problem.
